

SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan

Jing Yu, MD^{*1,2,3}, Wen Ouyang, MD^{*1,2,3}, Melvin L.K. Chua, MBBS FRCR PhD^{†1,4,5}, Conghua Xie, MD^{†1,2,3}

¹Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China, 430071.

²Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China, 430071.

³Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China, 430071.

⁴Division of Radiation Oncology, Division of Medical Sciences, National Cancer Centre Singapore

⁵Oncology Academic Programme, Duke-NUS Medical School, Singapore

*Both authors contributed equally as co-first authors

†Both authors contributed equally as co-senior authors

Running Title: COVID-19 in cancer patients

Word count: 613 words

Correspondence to:

Conghua Xie, MD, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People's Republic of China. E-mail: chxie_65@whu.edu.cn; Tel: +86-27-67812607; Fax: +86-27-67812889

Dr Melvin L. K. Chua, Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610. E-mail: melvin.chua.l.k@singhealth.com.sg; Tel: +65-64368000.

Abstract:

In December 2019, an outbreak of atypical pneumonia known as 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, China. This new type of pneumonia is characterized by rapid human-to-human transmission. Among the different disease types, cancer patients are often recalled to the hospital for treatment and disease surveillance, and the majority of cancer treatments such as chemotherapy and radiotherapy are immunosuppressive. This prompts us to consider if cancer patients were at an elevated risk of SARS-CoV-2 infection.

A total of 1,524 cancer patients who were managed at our tertiary cancer institution – Zhongnan hospital of Wuhan University were reviewed during the period of Dec 30, 2019 to Feb 17, 2020. It was found that cancer patients had an estimated 2-fold increased risk of COVID-19 than the general population. We identified twelve patients who were infected with SARS-CoV-2, with two recorded deaths (16.7%), albeit one patient passed away from a COVID-19 unrelated cause. Interestingly, only five of these patients were ongoing treatment at the time of contracting the virus, suggesting that hospital visitation was the likely factor contributing to the elevated incidence in cancer patients. Moreover, we also observed that the incidence of severe COVID-19 was not higher than in the general population. Consequently, for cancer patients who require treatment, proper isolation protocols must be in place to mitigate the risk of SARS-CoV-2 infection.

In December 2019, an outbreak of atypical pneumonia known as 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, Hubei, China. This new type of pneumonia is linked to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and is characterized by rapid human-to-human transmission, patients would develop progressive respiratory symptoms upon infection.¹ Droplet transmission appears to be the main route of transmission for SARS-CoV-2.² According to a recent report of 138 hospitalized patients from a single institution (Zhongnan Hospital of Wuhan University), it was indicated that hospital-acquired transmission accounts for 41.3% of these admitted patients (29% were hospital staff and 12.3% were in-house patients), thereby highlighting that the hospital environment may be a hotspot for viral spread.³ Among the different disease types, cancer patients are often recalled to the hospital for treatment and disease surveillance, and therefore, they may be at an elevated risk of contracting SARS-CoV-2. Moreover, the majority of cancer treatments such as chemotherapy and radiotherapy are immunosuppressive. Here, we report the incidence and outcomes of SARS-CoV-2 infection in cancer patients who were managed at a tertiary cancer institution in Wuhan.

We collected the data of all patients from Dec 30, 2019 to Feb 17, 2020 (data cut-off date) who were admitted to the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University. In total, 1,524 cancer patients were included in our study; the three commonest cancer diagnoses were gastrointestinal (N = 394, 35.9%), thoracic (N = 326, 21.4%), and head and neck cancers (N = 204, 13.4%). Among them, 12 patients were diagnosed with COVID-19 pneumonia (four by the

real-time reverse transcription polymerase chain reaction assay for SARS-CoV-2 and eight by the clinical criteria of fever and radiological computed tomography changes; **Table 1**). We estimated that the infection rate of SARS-CoV-2 in cancer patients from our single institution at 0.79% (95% CI = 0.3–1.2). This was higher than the cumulative incidence of all diagnosed COVID-19 cases that was reported in the city of Wuhan over the same time-period (0.37%, 41,152/11,081,000 cases, data cutoff on Feb 17, 2020).

Clinical details on the cancer history and COVID-19 pneumonia are summarized in Table 1. Among the SARS-CoV-2 infected patients, 58.3% (7 of 12) were non-small cell lung carcinoma patients. Five (41.7%) were on-going treatment with either chemotherapy +/- immunotherapy (N = 3) or radiotherapy (N = 2; one patient was undergoing concurrent chemoradiotherapy). Two patients (0.17%) developed severe adult respiratory distress syndrome (SARS), but none of the on-treatment patients required intensive-level care. Four patients (33.3%) have been discharged, and two deaths were recorded; one patient died from a COVID-19 unrelated cause.

It is hypothesized that cancer patients may be susceptible to an infection during a viral epidemic due to their compromised immune status, which may be induced by the treatment of the cancer. ⁴ Based on our single institution data, we observed that cancer patients from the epicenter of a viral epidemic indeed harbor a higher risk of SARS-CoV-2 infection (OR = 2.31, 95% CI = 1.89-3.02) when compared to the general community. Nonetheless, only less than half of these infected patients were undergoing active treatment for their cancers. It is arguable that a third of the patients

were terminally admitted for best supportive measures, and these patients are likely immunosuppressed. Regardless, our findings do imply that hospital admission and recurrent hospital visits are potential risks for SARS-CoV-2 infection, and these factors may account for the increased incidence among cancer patients. We therefore propose that aggressive measures are undertaken to reduce frequency of hospital visits during a viral epidemic going forward. For cancer patients who require treatment, proper isolation protocols must be in place to mitigate the risk of SARS-CoV-2 infection.





REFERENCES





1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* (London, England) 2020.
2. Expert consensus for bronchoscopy during the epidemic of 2019 Novel Coronavirus infection (Trial version). *Chinese journal of tuberculosis and respiratory diseases* 2020;43:E006.
3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama* 2020.
4. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. *The Lancet Oncology* 2009;10:589-97.




Table 1. Clinical characteristics and outcomes of cancer patients with severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Case	Sex	Age	P S	Cancer diagnosis	Phase of cancer treatment	Date of COVID-19 diagnosis	Date of first onset of symptoms	Fever	Dyspnea	Cough	CT diagnosis	SARS-COV- 2 RT-PCR assay	Severe events due to COVID-19	Hospitalization status	Survival status
1	Male	57	1	NSCLC	Concurrent EGFR TKI (osimertinib [80 mg/day]) with concurrent thoracic radiotherapy ((27 Gy in 9 fr))	2020/1/26	2020/1/18	Yes	No	No	Positive	Positive	No	Discharged	Alive
2	Male	69	1	NSCLC	W5 of chemoradiotherapy (Chemotherapy regime: pemetrexed [500mg/m ²], cisplatin [75mg/m ²] q3W; Radiotherapy 54 Gy in 27 fr)	2020/1/18	2020/1/17	Yes	Yes	Yes	Positive	Negative	No	Admitted	Alive
3	Female	78	3	NSCLC	Admitted for pleural effusion; best supportive care	2020/1/17	2020/1/17	Yes	Yes	Yes	Positive	Negative	No	Discharged	Alive
4	Male	60	1	NSCLC	Follow-up at 2 years post-chemoradiotherapy; no evidence of disease relapse	2020/2/14	2020/2/14	Yes	Yes	Yes	Positive	Negative	Yes	-	Dead
5	Male	69	1	NSCLC	Post-first cycle (docetaxel, [75mg/m ²], cisplatin [75mg/m ²], sintilimab, [200mg])	2020/1/22	2020/1/22	Yes	No	No	Positive	Negative	No	Discharged	Alive
6	Male	66	1	NSCLC	Post-third cycle (pemetrexed [500mg/m ²], carboplatin [AUC5], pembrolizumab [200mg])	2020/1/22	2020/1/22	Yes	No	No	Positive	Negative	No	Admitted	Alive
7	Male	65	1	NSCLC	Surgery (April 23th, 2019), Post-four cycles adjuvant chemotherapy (docetaxel [75mg/m ²], cisplatin [75mg/m ²])	2020/1/20	2020/1/20	Yes	No	No	Positive	Negative	No	Discharged	Alive
8	Male	76	2	Rectal cancer	Best supportive care	2020/1/22	2020/1/22	Yes	No	No	Positive	Negative	No	Admitted	Alive
9	Male	57	1	Colon cancer	Newly diagnosed; treatment yet to commence	2020/2/13	2020/1/21	Yes	No	No	Negative	Positive	No	Admitted	Alive
10	Male	67	3	Pancreatic cancer	Best supportive care	2020/1/22	2020/1/22	Yes	No	No	Positive	Negative	Yes	-	Dead
11	Female	48	1	Breast cancer	Adjuvant radiotherapy (42 Gy in 21 fr)	2020/1/26	2020/1/24	Yes	No	No	Positive	Positive	No	Admitted	Alive
12	Male	77	2	Urothelial cancer	Best supportive care	2020/2/17	2020/2/11	Yes	No	No	Not performed	Positive	No	Admitted	Alive

Abbreviations: PS, performance status; CT, computed tomography; RT-PCR, real-time quantitative polymerase chain reaction; COVID-19, 2019 coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; NSCLC, non-small cell lung cancer.

	Case 1	Case 2	Case 3	Case 4
Date of onset of symptoms	2020/1/18	2020/1/17	2020/1/17	2020/2/14
PCR assay	+ (D8)	- (D1)	- (D0)	- (D0)
CT diagnosis	+ (D2)	+ (D1)	+ (D0)	+ (D0)
				

	Case 5	Case 6	Case 7	Case 8
Date of onset of symptoms	2020/1/22	2020/1/22	2020/1/20	2020/1/22
PCR assay	- (D0)	- (D0)	- (D0)	- (D0)
CT diagnosis	+ (D0)	+ (D0)	+ (D0)	+ (D0)
				

	Case 9	Case 10	Case 11
Date of onset of symptoms	2020/1/21	2020/1/22	2020/1/24
PCR assay	+ (D23)	- (D0)	+ (D2)
CT diagnosis	- (D0)	+ (D0)	+ (D0)
			

medRxiv preprint doi: <https://doi.org/10.1101/2020.02.22.20025330>; this version posted February 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).